Tam-Peli is named as a drug or biological intervention in 8 clinical trials in our China, USA and UK trial registers, 5 of which are recruiting. Lead sponsors include MediLink Therapeutics (Suzhou) Co., Ltd. (7) and Amgen (1). Registered phases: Phase 3, Phase 1/2 and Phase 1. Conditions studied include Small Cell Lung Cancer; Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma; Advanced Solid Tumor.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Small Cell Lung Cancer | 2 |
| Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma | 1 |
| Advanced Solid Tumor | 1 |
| Advanced Esophageal Squamous Cell Carcinoma | 1 |
| Nasopharyngeal Carcinoma | 1 |
| Recurrent or Metastatic Nasopharyngeal Carcinoma | 1 |
| SCLC, Extensive Stage | 1 |
| Lead sponsor | Trials |
|---|---|
| MediLink Therapeutics (Suzhou) Co., Ltd. | 7 |
| Amgen | 1 |
| Register | Tam-Peli trials |
|---|---|
| Clinical trials in China | 7 |
| Clinical trials in USA | 3 |
| Clinical trials in UK | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Tam-Peli works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Tam-Peli (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.